Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy
|ClinicalTrials.gov Identifier: NCT01463059|
Recruitment Status : Completed
First Posted : November 1, 2011
Last Update Posted : March 25, 2013
UCB Japan Co. Ltd.
Information provided by (Responsible Party):
UCB Pharma ( UCB Japan Co. Ltd. )
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Completed|
|Primary Completion Date :||February 2013|
|Study Completion Date :||February 2013|
|Certification/Extension First Submitted :||March 19, 2013|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Takeuchi T, Tanaka Y, Yamanaka H, Amano K, Nagamine R, Park W, Shiozawa K, Tsukano M, Wei JC, Shao J, Togo O, Mashimo H. Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial. Mod Rheumatol. 2016;26(1):15-23. doi: 10.3109/14397595.2015.1074648. Epub 2015 Sep 10.